Scientists identify potential drug candidates for deadly pediatric leukemia

Scientists at Sanford Burnham Prebys have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children.

Conrad Prebys Foundation provides $3 million for pediatric brain cancer research

The Conrad Prebys Foundation provides $3 million to Robert Wechsler-Reya, Ph.D., and his team of researchers to advance a potential drug to treat medulloblastoma—the most common malignant brain tumor in children.

Alumni adventures: Catching up with student intern Daniel Million

Million reflects on how a summer internship at Sanford Burnham Prebys accelerated his scientific career.